Growth Differentiation Factor-15 and Syndecan-1 Are Potential Biomarkers of Cardiac and Renal Involvement in Classical Fabry Disease under Enzyme Replacement Therapy
Background and Aims: Inflammation and endothelial damage play a pivotal role in Fabry disease (FD) manifestations. In daily clinical practice, FD is mainly monitored by traditional biomarkers of target organ injury, such as serum creatinine and proteinuria, which provide no information about inflamm...
Main Authors: | Paulo C. Gregório, Gilson Biagini, Regiane S. da Cunha, Júlia Budag, Ana Maria Martins, Lara Valiño Rivas, Elberth M. Schiefer, Maria Dolores Sánchez-Niño, Alberto Ortiz, Andréa E. M. Stinghen, Fellype C. Barreto |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-01-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/521329 |
Similar Items
-
The Role of α3β1 Integrin Modulation on Fabry Disease Podocyte Injury and Kidney Impairment
by: Bruna Bosquetti, et al.
Published: (2023-12-01) -
Kidney Transplant in Fabry Disease: A Revision of the Literature
by: Irene Capelli, et al.
Published: (2020-06-01) -
Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis
by: Taciane Alegra, et al.
Published: (2012-01-01) -
Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
by: Il Young Kim, et al.
Published: (2021-12-01) -
Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
by: Gustavo Cabrera, et al.
Published: (2017-06-01)